# Late-Onset Treatment Study Extension Protocol

> **NCT00455195** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 81 (actual)

## Conditions studied

- Pompe Disease (Late-Onset)
- Glycogen Storage Disease Type II (GSD-II)
- Glycogenesis Type II
- Acid Maltase Deficiency (AMD)

## Interventions

- **BIOLOGICAL:** alglucosidase alfa

## Key facts

- **NCT ID:** NCT00455195
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-11
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2014-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455195, "Late-Onset Treatment Study Extension Protocol". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00455195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*